FY2023 EPS Estimates for Genmab A/S Boosted by William Blair (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB – Get Rating) – Investment analysts at William Blair upped their FY2023 earnings per share (EPS) estimates for shares of Genmab A/S in a report issued on Monday, May 22nd. William Blair analyst M. Phipps now expects that the company will earn $1.01 per share for the year, up from their previous forecast of $1.00. The consensus estimate for Genmab A/S’s current full-year earnings is $0.99 per share. William Blair also issued estimates for Genmab A/S’s Q4 2023 earnings at $0.39 EPS, FY2024 earnings at $1.30 EPS, FY2025 earnings at $1.73 EPS, FY2026 earnings at $2.24 EPS and FY2027 earnings at $2.88 EPS.

Other equities research analysts have also issued research reports about the company. Danske upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research note on Thursday, February 23rd. SVB Leerink increased their price target on shares of Genmab A/S from $33.00 to $36.00 and gave the company a “market perform” rating in a report on Monday, February 6th. Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Friday, May 12th. They issued an “underweight” rating for the company. Finally, HC Wainwright raised their price objective on shares of Genmab A/S from $47.00 to $51.00 in a research note on Monday. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Hold” and a consensus target price of $632.62.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $40.68 on Wednesday. Genmab A/S has a 52-week low of $26.19 and a 52-week high of $47.50. The firm has a market capitalization of $26.83 billion, a PE ratio of 36.65, a PEG ratio of 2.12 and a beta of 0.96. The stock has a fifty day simple moving average of $39.70 and a two-hundred day simple moving average of $40.58.

Genmab A/S (NASDAQ:GMAB – Get Rating) last issued its quarterly earnings results on Wednesday, February 22nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.23). Genmab A/S had a return on equity of 19.67% and a net margin of 34.34%. The business had revenue of $717.54 million during the quarter, compared to analysts’ expectations of $634.17 million.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Alliancebernstein L.P. acquired a new position in Genmab A/S during the third quarter valued at $185,695,000. First Trust Advisors LP acquired a new position in shares of Genmab A/S in the third quarter worth about $41,496,000. Millennium Management LLC raised its position in shares of Genmab A/S by 655.9% in the fourth quarter. Millennium Management LLC now owns 919,408 shares of the company’s stock worth $38,965,000 after acquiring an additional 797,770 shares during the period. Envestnet Asset Management Inc. raised its position in shares of Genmab A/S by 111.8% in the first quarter. Envestnet Asset Management Inc. now owns 1,109,871 shares of the company’s stock worth $16,936,000 after acquiring an additional 585,924 shares during the period. Finally, Lord Abbett & CO. LLC raised its position in shares of Genmab A/S by 279.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 645,551 shares of the company’s stock worth $27,358,000 after acquiring an additional 475,579 shares during the period. 6.73% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

(Get Rating)

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.